Ruxolitinib Might Be an Effective Hormone Reduction and Replacement Drug in Children With Secondary Hemophagocytic Lymphohistiocytosis

Ying Chi  
Capital Institute of Pediatrics

Rong Liu  
Capital Institute of Pediatrics

Zhixuan Zhou  
Capital Institute of Pediatrics

Xiaodong Shi  
Capital Institute of Pediatrics

Yuchuan Ding  
Capital Institute of Pediatrics

Jianguo Li (✉ jianguo_li6@hotmail.com)  
Children's Hospital Affiliated to the Capital Institute of Pediatrics, Beijing 100020, China.  
https://orcid.org/0000-0001-9431-2950

Research article

Keywords: Ruxolitinib, Hemophagocytic lymphohistiocytosis, Janus kinase inhibitor, Children

Posted Date: September 22nd, 2020

DOI: https://doi.org/10.21203/rs.3.rs-78746/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published at Pediatric Rheumatology on April 1st, 2021. See the published version at https://doi.org/10.1186/s12969-021-00534-0.
Abstract

**Background:** To analyze the effects of ruxolitinib on children with secondary hemophagocytic lymphohistiocytosis (HLH).

**Methods:** Eleven pediatric patients diagnosed with HLH and treated with ruxolitinib (ruxolitinib group: group R) between November 2017 and August 2018 were retrospectively analyzed. Eleven age-matched pediatric patients with HLH undergoing conventional treatment (control group: group C) were also analyzed.

**Results:** In group R, three patients who did not respond to conventional treatment (dexamethasone and etoposide) were treated with Ruxolitinib and their temperature decreased to normal levels. Four patients had normal temperature after conventional treatment, but they had severe organ involvement, including obvious yellowing of the skin, increased liver enzyme levels and neuropsychiatric symptoms, and they were all ameliorated with ruxolitinib treatment. Four patients were relieved with ruxolitinib therapy alone. In group C, the body temperature of eleven patients all decreased to normal levels after conventional treatment. The body temperature of group R patients decreased to normal levels more rapidly than that of group C patients. The hormone dosage in group R was significantly lower than that in group C. Both groups were followed up for 2–2.5 years. No obvious adverse drug reactions of ruxolitinib were observed during treatment and follow-up.

**Conclusion:** Ruxolitinib might be an effective drug in controlling body temperature and reducing inflammation indicators. It might be a potential replacement for hormone therapy for HLH treatment in children, thereby reducing or avoiding hormone-related adverse reactions.

1. Background

Hemophagocytic syndrome is also known as hemophagocytic lymphohistiocytosis (HLH). This rare life-threatening syndrome is characterized by excessive proliferation and activation of lymphocytes caused by cytokine storms and severe systemic inflammatory responses. According to the accepted doctrine, the pathogenesis of HLH is closely associated with the “cytokine storm”.1 Depending on the etiology, there are two forms of HLH: primary autosomal recessive inheritance, also known as familial hemophagocytic lymphohistiocytosis, and secondary HLH, which develops because of strong immune activation. Primary HLH is mostly caused by genetic defects leading to immune system dysfunction. Infection, connective tissue disease, and malignancy are considered as common causes of secondary HLH.2-4 Epstein-Barr virus (EBV), a DNA virus and member of the *Herpesviridae* family, has been consistently associated with HLH.5-15

HLH in children is a rare disease with a high fatality rate. Studies have shown that most cytokines related to HLH are activated through activation of the Janus Kinase (JAK)/signal transducer and activator of transcription signaling pathway, which not only regulates the biological activity of cytokines, but also
affects the differentiation of primary T cells into T helper (TH) cell families, TH1, TH2, TH17, and regulatory T cells.  

According to the HLH-2004 diagnostic criteria, a diagnosis of HLH can be made if five of the following eight criteria are fulfilled: (1) fever, (2) splenomegaly, (3) cytopenias (affecting ≥2 of three lineages in peripheral blood; hemoglobin <90 g/L, platelets <100 × 10⁹/L, neutrophils <1.0 × 10⁹/L), (4) hypertriglyceridemia and/or hypofibrinogenemia, (5) hemophagocytosis in the bone marrow or spleen or lymph nodes (no evidence of malignancy), (6) low or absent natural killer (NK) cell activity (according to local laboratory reference), (7) ferritin ≥500 µg/L, and (8) soluble cluster of differentiation 25 (i.e., soluble interleukin-2 (IL-2) receptor (IL-2R)) ≥2400 U/mL.

The above clinical and laboratory findings are related to the pathophysiology of HLH. High interleukin levels cause fever. Elevated ferritin >10,000 µg/L has been demonstrated to be 90% sensitive and 96% specific for HLH. Activation of lymphocytes can result in high concentrations of soluble IL-2 receptor.  

Most clinicians still adopt the HLH-04 protocol recommended by the Histiocyte Society for the treatment of HLH. Conventional treatment options typically include three phases of induction therapy, maintenance therapy, and/or hematopoietic stem cell transplantation. The drugs for HLH include dexamethasone, cyclosporine A, and etoposide. However, a multi-center study in 2016 revealed no significant benefit from cyclosporine and intrathecal injections, and macrophage activation syndrome secondary to connective tissue disease is not always treated with the HLH-04 regimen. The five-year survival rate for secondary HLH in adults worldwide is approximately 54% and the survival rate reported in China is even lower, ranging from 31.7–56.1%. Hence, less toxic, more effective, and better targeted immunosuppressive treatments in HLH are urgently needed.

In recent years, JAK inhibitors have been the focus of research on new small molecule targeted therapies and can be used for the treatment of inflammatory diseases such as hematological diseases, tumors, rheumatoid arthritis, ulcerative colitis, and other autoimmune diseases. Ruxolitinib is a Janus-associated kinase 1/2 (JAK1/2) inhibitor that impedes downstream signaling pathways of cytokines such as interferon-γ, IL-2, and IL-6 to reduce inflammatory responses triggered by these cytokines, which play important roles in HLH. Ruxolitinib was found to control inflammatory storms and prolong survival in secondary HLH model mice; this treatment was effective in 10 cases of HLH, including one child from abroad.

Herein, we present 11 cases of children treated with ruxolitinib. We compared the effects of ruxolitinib administration in children with HLH to the effects of conventional therapy in a control group of children with HLH; both groups were followed up for 2–2.5 years.

2. Materials And Methods
2.1 Patients: A study was performed on 11 children diagnosed with HLH and treated with ruxolitinib (group R) and 11 children with HLH who were age-matched and were not administered ruxolitinib during the same period (group C). The diagnosis was made between November 2017 and August 2018 with a follow-up endpoint in February 2020. This study was reviewed by the Hospital Ethics Committee; informed consent was obtained from the patients’ parents, who had signed a written instrument, prior to the use of ruxolitinib and specimen collection.

2.2 Inclusion criteria: Compliance with HLH-2004 diagnostic criteria\(^2\) was the inclusion criterion for this study.

2.3 Exclusion criteria: Children underwent purified protein derivative skin test, chest radiography, high-resolution computed tomography if necessary, and T-SPOT (T-cell enzyme immuno-spotting) to confirm the absence of tuberculosis infection, which was the exclusion criterion for this study.

2.4 Etiological analysis: All children were tested for bacteria, viruses, fungi, and parasites. Whole exome sequencing was performed for all cases in group R and no known pathogenic genes were found.

2.5 Treatment: Four patients in group R were treated with ruxolitinib alone and five patients were treated with ruxolitinib following the failure of previous therapy. The dosage used in this study was the same as that used to treat graft-versus-host disease: 2.5 mg/dose orally twice daily for those with body weight \(\leq 25\) kg and 5 mg/dose orally twice daily for those with body weight \(>25\) kg\(^3\). Children with viral infections were also treated with antiviral therapy. Group C was treated with the conventional treatment (dexamethasone and etoposide).

2.6 Follow-up: Monitoring of clinical symptoms, such as body temperature and hepatosplenomegaly, and determination of blood routine, blood biochemistry, coagulation function, C-reactive protein, erythrocyte sedimentation rate, ferritin, cytokines, and NK cell activity were performed. The children were followed-up in outpatient clinics to record their clinical symptoms, treatment status, and outcomes once every month for the first, second, and third months, and then once every 3 months, and once every 6 months after 1 year, for a total of 2-2.5 years.

2.7 Safety evaluation: Symptoms of discomfort after taking medication were recorded. Liver and kidney functions, as well as whether the patients had co-infections were monitored.

2.8 Statistical analysis: SPSS Statistics 24 (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. For continuous data, normal distribution was expressed as the\(\bar{x} \pm s\), and the independent sample \(t\)-test was used. Data that did not meet the normal distribution were expressed as \(M (P25, P75)\), and the Wilcoxon rank-sum test was used. For continuous data from \(\geq 3\) measurements, the repeated-measures design data analysis of variance was used. Categorical variables were represented by \(N (\%)\), and chi-square test was used. \(P < 0.05\) was considered as statistically significant.

3. Results
### 3.1 General information

Group R consisted of 11 children: six girls (54.5%) and five boys (45.5%); aged 1–6 years, with a median age of 3.3 years. The course of HLH prior to ruxolitinib administration varied from 4 days to 2 months. Group C consisted of 11 children: five girls (45.5%) and six boys (54.5%); aged 1–8 years, with a median age of 3.8 years. There was no significant difference in the age and sex of the children in the two groups. Information on clinical features, underlying diseases, and therapy prior to ruxolitinib administration of group R is shown in Table 1.

**TABLE 1. Clinical features, underlying diseases, and therapy of the two groups of patients**

| Clinical features | Group R before ruxolitinib [number [percentage (%)]] | Group C number [percentage (%)] |
|-------------------|-----------------------------------------------------|---------------------------------|
| Fever ≥ 38.5°C    | 11 (100)                                            | 11 (100)                        |
| Splenomegaly      | 11 (100)                                            | 11 (100)                        |
| Cytopenias        | 11 (100)                                            | 10 (90.91)                      |
| Hypofibrinogenemia/Hypertriglyceridemia | 11 (100)                      | 10 (90.91)                      |
| Elevated ferritin | 11 (100)                                            | 11 (100)                        |
| Hemophagocytosis  | 7 (63.64)                                            | 7 (63.64)                       |
| Low or absent NK-cell activity | 4 (36.36)    | 7 (63.64)                       |
| Elevated soluble CD25 | 7 (63.64)       | 7 (63.64)                       |
| Underlying diseases |                                                  |                                 |
| Infection         | 8 (72.73)                                            | 4 (36.36)                       |
| Juvenile idiopathic arthritis (systemic type) | 2 (18.18)    | 6 (54.55)                       |
| Kawasaki disease  | 1 (9.10)                                             |                                 |
| Systemic lupus erythematosus | 1 (9.10)                 |                                 |
| Therapy           |                                                     |                                 |
| HLH-04            | 6 (54.55)                                            | 6 (54.55)                       |
| Hormone and IVIG  |                                                     | 5 (45.45)                       |
| HLH-04 and IVIG   | 3 (27.27)                                            |                                 |
| IVIG              | 2 (18.18)                                            |                                 |

NK-cell: natural killer cell; HLH: hemophagocytic lymphohistiocytosis; IVIG: intravenous immunoglobulin; group R, ruxolitinib-treated group; group C, control group treated with conventional therapy.
3.2 Etiology: In group R, 8 cases (72.72%) had the cause of infection, including 5 cases of Epstein-Barr virus (EBV) infection, 1 case of hepatitis B virus (HBV) infection (Li et al., in press), 1 case of cytomegalovirus infection, and 1 case of influenza virus infection; the other 3 cases had no cause of infection: two cases (18.18%) were juvenile idiopathic arthritis (systemic type), and one case (9.1%) was Kawasaki disease. In group C, 4 cases (36.36%) had the cause of infection, including 2 cases of EB virus infection and 2 cases of parainfluenza virus infection. 6 cases (54.54%) with no infection manifested as juvenile idiopathic arthritis (systemic type), and 1 case (9.1%) with systemic lupus erythematosus in children. In all 11 cases of group R, no known gene mutation was detected by whole exon gene analysis, which was considered as secondary HLH.

3.3 Severe organ involvement: In group R, R4 had obvious skin yellowing, liver damage, and cholestasis; R6 and R7 had CNS involvement such as convulsions, drowsiness, and coma; R6 also had pulmonary hemorrhage and gastrointestinal bleeding. In group C, C4 had liver damage, coronary artery dilation, and pulmonary hypertension; C9 had bronchopneumonia, thrush, and febrile convulsions.

3.4 Efficacy of ruxolitinib therapy in group R: The body temperature of R1-R3 did not decrease with conventional treatment but returned to normal levels following administration of ruxolitinib. The temperature of R3 rose again after 3 days of ruxolitinib therapy but stabilized once the dose was increased from 2.5 mg bid (twice daily) to 3.75 mg bid (Figure 1). Although the body temperature of R4–R7 decreased to normal levels after conventional treatment, but they had severe organ involvement, including obvious liver damage and neuropsychiatric symptoms. They were all ameliorated by ruxolitinib treatment. R8–R11 were treated with ruxolitinib immediately after diagnosis. All children had normal body temperature at 3 days after treatment (Figure 2).

3.5 Changes in body temperature between two groups: There were no significant differences in body temperature between the two groups before treatment (P = 0.24). In group R, the children's body temperature decreased to normal levels after 2 days of treatment and remained stable. In group C, the body temperature of eight patients decreased to normal levels after 3 days of treatment, whereas the body temperature of the other three cases returned to normal levels after 5–6 days of treatment. However, fever recurred in eight patients in group C at 2–7 days after the body temperature had normalized and had to be controlled with immunosuppressants. Figure 3 shows the rapid temperature decrease in group R patients compared to in group C patients: the temperature of group R patients was significantly lower than that of group C patients on days 2–3 and 7–9 after treatment (Pd2 = 0.022, Pd3 = 0.014, Pd7 = 0.003, Pd8 = 0.020, Pd9 = 0.031).

3.6 Changes in laboratory values (Table 2): Following treatment with ruxolitinib, the white blood cell (WBC) count and fibrinogen levels gradually increased, whereas ferritin and IL-2R levels gradually decreased. The differences in WBC, fibrinogen, ferritin, and IL-2R levels of two groups were significant compared to prior treatment (P values were 0.002, <0.001, <0.001, and 0.036, respectively). One week and one month after treatment, the WBC levels in group R patients showed significantly rapid improvement compared to those in group C patients (P1w = 0.037, P1m = 0.002). There was no significant difference in
the ferritin levels of the two groups of patients (P1w = 0.398, P1m = 0.064). Although there were no significant differences in the fibrinogen and IL-2R levels of the two groups after 1 week (P1w distribution is 0.74, 0.062), these levels showed significantly rapid improvement in R group patients compared to those in group C patients after one month (P1m distribution is 0.035, 0.041). In group R, five cases of EBV infection, one case of HBV infection, one case of cytomegalovirus infection, and one case of influenza virus infection were treated with a combination of ruxolitinib and antiviral drugs, after which these patients tested negative for antiviral antibodies and their viral DNA copy numbers had decreased. In group C, there were 2 cases with Epstein-Barr virus infection and 2 cases with parainfluenza virus infection. After traditional therapy combined with antiviral drugs, the clinical symptoms improved, the virus antibody turned negative, and the DNA copy number decreased.

TABLE 2 Changes in laboratory indices after treatment

| Laboratory index | Group | Before treatment | 1 week after treatment | 1 month after treatment | F     | P     |
|------------------|-------|------------------|------------------------|------------------------|-------|-------|
| WBC (×10⁹/L)     |       | R                | 2.55±2.21              | 5.45±3.32              | 8.896 | 0.002 |
|                  |       | C                | 4.29±3.37              | 8.77±4.69              | 9.62±5.17 |
| Fibrinogen (g/L) |       | R                | 0.9±0.35               | 1.65±0.66              | 2.17±0.89 | 86.247 | <0.001 |
|                  |       | C                | 1.98±0.31              | 2.62±0.21              | 3.94±1.45 |
| Ferritin (ng/mL) |       | R                | 17090±17586            | 828.1±646.4            | 178.9±166.1 | 22.493 | <0.001 |
|                  |       | C                | 12579±18748            | 4765.6±4562.2          | 597.6±783.3 |
| IL-2R (U/mL)     |       | R                | 9381.3±12865.4         | 2540±1381.5            | 494.2±195.8 | 5.146 | 0.036 |
|                  |       | C                | 1784.5±516.4           | 760±155.6              | 390±84.8 |

WBC, white blood cell; IL-2R, interleukin-2 receptor; group R, ruxolitinib-treated group; group C, control group treated with conventional therapy.

3.7 Hormone dosage (Figure 4): One and two months after discharge, the oral doses of methylprednisolone in both groups were significantly lower than those at discharge (F = 60.536; P < 0.001). Compared with group C, the average dose of methylprednisolone in children in group R was significantly reduced (F = 29.756, P < 0.001).

3.8 Safety evaluation of ruxolitinib: No headache, dizziness, or other discomfort; no gastrointestinal reactions such as nausea and vomiting; no obvious infection; no thrombocytopenia, neutropenia, or anemia; no impairment of liver or kidney function; no increase in triglyceride and cholesterol levels; and no other adverse drug reactions were observed after treatment with ruxolitinib.

3.9 Follow-up: The patients were followed up for 2–2.5 years (average of 2.4 years). In group R, the dosage of the hormone was first reduced, and the used of ruxolitinib was discontinued after 3 months of
administration. Follow-up was continued for 21–27 months. One child presented with recurrent fever, accompanied by joint swelling and pain, and was diagnosed with juvenile idiopathic arthritis; the child improved after treatment with tocilizumab. In group C, three children with juvenile idiopathic arthritis experienced recurrent symptoms after hormone reduction, presenting as fever with joint swelling and pain; they also improved after treatment with tocilizumab.

4. Discussion

In this study, we found that administration of ruxolitinib to children with HLH was effective for controlling their body temperature, improving inflammatory indices (ferritin, IL-2R), and ameliorating symptoms of CNS involvement. Combining hormones and antiviral agents resulted in the resolution of viral infection and reduction in the dosage of hormones.

Hermans et al. found that administration JAK inhibitors significantly inhibited the degranulation of mast cells and reduced the production of cytokines in an in vitro study of lymphocytes. Ruxolitinib also reversibly improved the killing and degranulation of NK cells and ameliorated organ damage in HLH animal models. In 2016, Das et al. used lymphocytic choriomeningitis virus to infect perforin-deficient mice and construct a model of secondary HLH. A large dose of ruxolitinib (90 mg/kg) not only improved the disease symptoms and decreased cytokine levels in HLH model mice, but also increased the survival rates in mice. A small dose of ruxolitinib (1 mg/kg) also significantly improved long-term survival and clinical symptoms and promoted liver tissue regeneration. Subsequently, a case of an 11-year-old child with refractory HLH who was treated with a combination of dexamethasone, etoposide, ruxolitinib (2.5 mg), and alemtuzumab was reported. Inflammatory factor levels rapidly decreased, organ function was restored, and no HLH relapse was observed even after etoposide treatment was discontinued.

Ruxolitinib was used as first-line treatment with dexamethasone in a 71-year-old patient with HLH. Administration of ruxolitinib (10 mg/dose, twice daily) was started on the 8th day of hospitalization; the patient's condition and laboratory values improved on the 15th day of hospitalization. A 38-year-old patient was treated with dexamethasone, immunoglobulin, etoposide, and rituximab; after administration of ruxolitinib (20 mg/dose, twice daily), there was an improvement in the patient's phagocytic indicators such as serum ferritin, lactate dehydrogenase, and fibrinogen levels, but the patient eventually died of intracranial bleeding and multiple organ failure.

In this study, refractory cases of HLH were treated with ruxolitinib, resulting in the regulation of body temperature and inflammatory factors and improvement of CNS involvement. In addition, administration of ruxolitinib reduced the hormone dose, which is important for the growth and development of children.

Five cases (R1–R5) in group R had recurrent fever and showed no improvement in clinical features or inflammatory indicators such as IL-2R, ferritin, and C-reactive protein levels despite hormonal, immunosuppressive, and immunoglobulin therapies; hence, ruxolitinib was added to their treatment regimen. Their body temperature subsequently dropped rapidly and inflammatory indicators improved, demonstrating that ruxolitinib controlled the body temperature and inhibited the inflammatory response.
Two cases (R6, R7) with CNS involvement showed no improvement in neuropsychiatric symptoms after termination of the HLH-04 regimen, but gradually recovered with administration of ruxolitinib, suggesting a positive effect with CNS involvement. However, other studies have shown unsatisfactory therapeutic effects of ruxolitinib in patients with HLH combined with CNS involvement, attributing the lack of efficacy to its large molecular weight which prevents its penetration across the blood-brain barrier to act on the CNS. This contradictory evidence warrants further study.

Four cases (R8–R11) were treated with ruxolitinib directly without using the HLH-04 regimen. One patient was diagnosed with HLH and HBV and was reported in the journal of Pediatric. As immunosuppressants and hormones may aggravate HBV infection, the child was treated with ruxolitinib combined with antiviral therapy using entecavir. All disease indicators improved significantly. During follow-up after more than 1 year, the body temperature of the child remained stable, and HBV-DNA was undetectable because of the treatment with antiviral drugs. This is the first study to use ruxolitinib alone to treat HLH. The other three children also had normal body temperature after treatment with ruxolitinib, and all indicators showed improvement.

Compared with group C, the dosage of hormones in R group children was apparently reduced throughout the treatment, suggesting that ruxolitinib can reduce the dosage of hormones or even replace hormone therapy, thereby reducing or avoiding hormone-related adverse reactions.

In children with co-infections, including EBV and HBV, there was no exacerbation of existing infections during ruxolitinib administration combined with antiviral therapy.

During the 2–2.5 years of follow-up, no children in group R had any co-infections or recent adverse reactions. One patient developed fever again following discontinuation of ruxolitinib and had joint swelling and pain. That patient was diagnosed with juvenile idiopathic arthritis, and the patient's condition improved after treatment with tocilizumab.

**5. Conclusion**

To date, there have been a few reports of individual cases being treated with ruxolitinib. In this study, we present 11 cases of children treated with ruxolitinib, demonstrating that ruxolitinib might be effective for treating HLH and is convenient to administer. It may be used as a first-line treatment for HLH with hormone reduction. Treatment with ruxolitinib also improved the symptoms of inflammatory factors and CNS involvement in refractory HLH. A limitation of this study was the small sample size. In future studies, a large sample cohort should be used to confirm the safety, optimal dosage, treatment duration, withdrawal criteria, long-term effects, and efficacy of ruxolitinib in HLH caused by different etiologies. The findings of this study indicate that ruxolitinib can partially replace hormones and become a potential first-line drug for the treatment of HLH, which is important for the growth and development of children.

**Abbreviations**
HLH: hemophagocytic lymphohistiocytosis
JAK: Janus Kinase
TH cell: T helper cell
NK cell: natural killer cell
IL-2R: interleukin-2 receptor
T-SPOT: T-cell enzyme immuno-spotting
EBV: Epstein-Barr virus
HBV: hepatitis B virus
WBC: white blood cell
MP: methylprednisolone
ESR: erythrocyte sedimentation rate
CRP: C-Reactive protein

**Declarations**

**Acknowledgments**

We would like to thank our patient for generously agreeing to share her case for publication.

**Authors’ contributions**

Jian-guo Li took primary responsibility for the paper. Jian-guo Li and Ying Chi designed the research; Rong Liu, Zhi-xuan Zhou and Xiao-dong Shi performed the research, contributed analytical tools, and collected the data; Ying Chi analysed and interpreted the data; Yu-chuan Ding formed statistical analyses; Ying Chi wrote the manuscript.

**Funding**

This study was funded by the Beijing Municipal Administration of Hospitals Clinical Medicine Development of special funding support (#XMLX201813) and the Capital’s Funds for Health Improvement and Research (#2020-2-2102).

**Availability of data and materials**
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

The study was reviewed and approved by the Hospital Ethics Committee of Capital Institute of Pediatrics.

**Consent for publication**

Written consent was obtained.

**Competing interests**

The authors declare that they have no competing interests.

**References**

1. Brisse E, Wouters CH, Matthys P. Hemophagocytic lymphohistiocytosis (HLH): A heterogeneous spectrum of cytokine-driven immune disorders. Cytokine Growth Factor Rev 2015;26:263–280.

2. Henter JI, Horne A, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124–131.

3. Jiménez-Hernández E, Martinez-Villegas O, Sánchez-Jara B, et al. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: response to HLH-04 treatment protocol. Bol Med Hosp Infant Mex 2016;73:26–30.

4. Dhote R, Simon J, Papo T, et al. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum 2003;49:633–639.

5. Belyea B, Hinson A, Moran C, Hwang E, Heath J, Barfield R. Spontaneous resolution of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2010;55:754–764.

6. Beutel K, Gross-Wieltsch U, Wiesel T, Stadt UZ, Janka G, Wagner HJ. Infection of T lymphocytes in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children of non-Asian origin. Pediatr Blood Cancer 2009;53:184–190.

7. Fisman DN. Hemophagocytic syndromes and infection. Emerg Infect Dis 2000;6:601–608.

8. Buza N, Bálint I, Schneider T, Koltai L, Orosz Z. Unusual clinical manifestation of virus-associated hemophagocytic syndrome. Pathol Res Pract 2003;199:755–759.

9. Chuang HC, Lay JD, Hsieh WC, et al. Epstein-Barr virus LMP1 inhibits the expression of SAP gene and upregulates Th1 cytokines in the patho-genesis of hemophagocytic syndrome. Blood 2005;106:3090–3096.

10. Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol 2013;162:376–382.
11. George TI, Jeng M, Berquist W, Cherry AM, Link MP, Arber DA. Epstein-Barr virus-associated peripheral T-cell lymphoma and hemophagocytic syndrome arising after liver transplantation: case report and review of the literature. Pediatr Blood Cancer 2005;44:270–276.

12. Fox CP, Shannon-Lowe C, Gothard P, et al. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults characterized by high viral genome load within circulating natural killer cells. Clin Infect Dis 2010;51:66–69.

13. George MR, Herman JH, Holdbrook T, Cui C, Vardhana HG, Behling EM. Platelet refractoriness in acquired hemophagocytic syndrome. Transfusion 2011;51:2319–2326.

14. Gonzalo DH, Rodriguez G, Marcilla D. Diagnostic difficulties of the hemophagocytic lymphohistiocytosis (HLH) associated with the Epstein-Barr virus. J Pediatr Hematol Oncol 2007;29:206–207.

15. Halasa NB, Whitlock JA, McCurley TL, et al. Fatal hemophagocytic lymphohistiocytosis associated with Epstein-Barr virus infection in a patient with a novel mutation in the signaling lymphocytic activation molecule-associated protein. Clin Infect Dis 2003;37:e136–e141.

16. Terrén I, Mikelez I, Odriozola I, et al. Implication of Interleukin-12/15/18 and Ruxolitinib in the phenotype, proliferation, and polyfunctionality of human cytokine-preactivated natural killer cells. Front Immunol 2018;9:737.

17. Aricó M, Janka G, Fischer A, et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. Leukemia 1996;10:197–203.

18. Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2008;50:1227–1235.

19. Lin TF, Ferlic-Stark LL, Allen CE, Kozinetz CA, McClain KL. Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatr Blood Cancer 2011;56:154–155.

20. Imashuku S. Hyperferritinemia in hemophagocytic lymphohistiocytosis and related diseases. Pediatr Blood Cancer 2008;51:442.

21. Henter JI. Pronounced hyperferritinemia: expanding the field of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2008;50:1127–1129.

22. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr 2007;166:95–109.

23. Bergsten E, Home A, Aricó M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long term results of the cooperative HLH-2004 study. Blood 2017;130:2728–2738.

24. Wang Z, Wang Y, Huang W, et al. Hemophagocytic lymphohistiocytosis is not only a childhood disease: A multi-center study of 613 cases from Chinese HLH Work group. Blood 2014;124:41–46.

25. Li F, Yang Y, Jin F, et al. Clinical characteristics and prognostic factors of adult hemophagocytic syndrom patients: a retrospective study of increasing awareness of a disease from a single-center in China. Orphanet J Rare Dis 2015;10:20.
26. Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity 2012;36:503–514.
27. Wang JS, Wang YN, Wu L, Lai WY, Wang Z. [Refractory/relapsed hemophagocytic lymphohistiocytosis treated with ruxolitinib—three cases report and literatures review.] Zhonghua Xue Ye Xue Za Zhi 2019;40:73–75.
28. Trantham T, Auten J, Muluneh B, Van Deventer H. Ruxolitinib for the treatment of lymphoma-associated hemophagocytic lymphohistiocytosis: A cautionary tale. J Oncol Pharm Pract 2020;26:1005–1008.
29. Goldsmith SR, Saif Ur Rehman S, Shirai CL, Vij K, DiPersio JF. Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib. Blood Adv 2019;3:4131–4135.
30. Broglie L, Pommert L, Rao S, et al. Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. Blood Adv 2017;1:1533–1536.
31. Slostad J, Hoversten P, Haddox CL, Cisak K, Paludo J, Tefferi A. Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience. Am J Hematol 2018;93:E47–E49.
32. Sin JH, Zangardi ML. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report. Hematol Oncol Stem Cell Ther 2019;12:166–170.
33. Spoerl S, Mathew NR, Bacheiner M, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood 2014;123:3832–3842.
34. Hermans MAW, Schrijver B, van Holten·Neelen CCPA, et al. The JAK1/JAK2 inhibitor Ruxolitinib inhibits mast cell degranulation and cytokine release. Clin Exp Allergy 2018;48:1412–1420.
35. Schönberg K, Rudolph J, Vonnahme M, et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res 2015;75:2187–2199.
36. Curran SA, Shyer JA, St Angelo ET, et al. Human dendritic cells mitigate NK cell dysfunction mediated by nonselective JAK1/2 blockade. Cancer Immunol Res 2017;5:52–60.
37. Das R, Guan P, Sprague L, et al. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood 2016;127:1666–1675.
38. Maschalidi S, Sepulveda FE, Garrigue A, Fischer A, de Saint Basile G. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood 2016;128:60–71.
39. Gadina M. Janus kinases: an ideal target for the treatment of autoimmune diseases. J Investig Dermatol Symp Proc 2013;16:S70–S72.

Figures
Figure 1

Daily temperature peak of patients (R1-R3) in the hospitalization. The body temperature rapidly returned to normal after 2 days of ruxolitinib treatment. Abbreviations: Rux=ruxolitinib
Figure 2

Body temperature of patients (P8-11): Body temperature returned to normal after 3 days of ruxolitinib treatment.
Figure 3

Mean body temperature of two groups: Body temperature returned to normal after 3 days of ruxolitinib treatment. The mean body temperature of group R patients was lower than that of group C patients.

Figure 4

Comparison of MP oral doses between both groups after discharge. Compared with group C, the average dose of MP in children in group R was significantly reduced. Abbreviations: MP, methylprednisolone; group R, ruxolitinib-treated group; group C, control group treated with conventional therapy.